Triple-negative breast cancer (TNBC), defined as a subtype expressing less estrogen receptor (ER), progesterone receptor (PgR), and human epithelial growth factor receptor (HER2) by immunohistochemistry, accounts for approximately 15% of all breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.